Recent Investment Analysts’ Ratings Updates for AstraZeneca (AZN)

AstraZeneca (NASDAQ: AZN) has recently received a number of price target changes and ratings updates:

• 12/10/2025 – AstraZeneca had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $108.00 price target on the stock.
• 12/9/2025 – AstraZeneca had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/3/2025 – AstraZeneca had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/3/2025 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $103.00 price target on the stock.
• 10/27/2025 – AstraZeneca is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating on the stock.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.